Novo Nordisk, the Denmark-based pharmaceutical major, has formally introduced its widely used diabetes and weight-management drug Ozempic in the Indian market. According to Reuters, the drug’s lowest weekly dose has been priced at ₹2,200 (around $24.35). The launch is seen as a significant development for diabetes treatment in India, where the burden of metabolic disorders continues to grow.
Ozempic: dosage, pricing and availability
Ozempic, whose active ingredient is semaglutide, is a once-weekly injectable medication prescribed for type 2 diabetes and frequently used off-label for weight reduction because of its appetite-suppressing effect. As per Reuters, the drug will be available nationwide in three dosage strengths 0.25 mg, 0.5 mg and 1 mg.
The introductory 0.25 mg dose is priced at ₹2,200 per week, with higher strengths costing more in line with Novo Nordisk’s global pricing framework adapted for India.
The launch has generated strong interest among doctors and patients, reflecting Ozempic’s global popularity and robust clinical evidence. Its entry into India is expected to expand treatment choices for the country’s large population living with diabetes and related metabolic conditions.
Patent challenges before Indian courts
Ozempic’s India debut coincides with ongoing patent litigation involving Novo Nordisk and leading domestic drug manufacturers over semaglutide.
- Sun Pharmaceutical Industries: Novo Nordisk approached the Delhi High Court seeking to restrain Sun Pharma from introducing a semaglutide-based weight-loss drug in India, citing patent infringement. The court allowed Sun Pharma to manufacture and export the product to countries where Novo Nordisk does not hold patent protection, but prohibited its sale in India until March 2026, when key patents are set to expire.
- Dr Reddy’s Laboratories: In a separate matter, the Delhi High Court declined Novo Nordisk’s request to block Dr Reddy’s from producing semaglutide for export. The case is scheduled for further hearing in January, as Indian drugmakers gear up for intensified competition following patent expiry in 2026.
Implications for patients
For Indian patients and healthcare professionals, the local launch of Ozempic represents improved access to a globally established diabetes therapy. With lifestyle-related diseases on the rise, the availability of advanced treatment options at relatively accessible prices could play an important role in improving long-term health outcomes.